PeptideScanner retained ClinicalTrials.gov record NCT03596905 at 2026-07-30T18:18:33.534Z. Its registry update date was 2025-12-31, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06921824 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07300982 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05568160 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00117286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06588504 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07104500 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-11-24, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06052787 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05929339 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-10-28, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.
PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03069937 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-10-15, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.
PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT06872060 at 2026-07-30T18:20:54.427Z. Its registry update date was 2025-10-03, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.
PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT04321408 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-17, and PeptideScanner's reviewed identity mapping was ziconotide.
PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05821075 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-07-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03241706 at 2026-07-30T18:24:37.180Z. Its registry update date was 2025-07-25, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07073014 at 2026-07-30T18:24:37.179Z. Its registry update date was 2025-07-18, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02078726 at 2026-07-30T18:24:37.187Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03532399 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT06745128 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06073184 at 2026-07-30T18:26:04.258Z. Its registry update date was 2025-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT00667069 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-06-05, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT03651765 at 2026-07-30T18:27:14.161Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT06974344 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03289741 at 2026-07-30T18:27:14.159Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT05467033 at 2026-11-16T01:33:21.554Z. Its registry update date was 2025-05-08, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01220869 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT06547892 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06918405 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT05506319 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02457156 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06861374 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-03-06, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00463983 at 2026-07-30T18:30:10.977Z. Its registry update date was 2025-03-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02505984 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT03480698 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT05755997 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT03846505 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT04057131 at 2026-11-15T22:04:12.435Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT03847207 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-02-19, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT05203237 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-17, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT06068946 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-12, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT04725240 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT03133195 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-15, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06456359 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-01-13, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide.